The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure.

This article focuses on the potential role of mineralocorticoid receptor antagonists (MRAs) in patients with stage B heart failure (HF) due to hypertension, diabetes mellitus, and/or visceral obesity with the metabolic syndrome. It briefly discusses the role of MRAs in patients with left ventricular dilatation due to nonischemic or ischemic cardiomyopathy and in those with a prior myocardial infarction but without left ventricular dilatation or evidence of HF.